Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propensity Score Analysis

Table 2

Univariate and multivariate analysis OS.

Variable	Univariate			Multivariate
	HR	95% CI	value	HR	95% CI	value
Age (≥66 years versus <66 years)	0.7	0.4–1.3	0.27
Gender (female versus male)	1.3	0.71–2.41	0.38
Tumor location (nonhead versus head)	1.3	0.7–2.4	0.4
Karnofsky performance status score (100–80% versus 70–60%)	0.3	0.12–0.69	0.005	0.4	0.2–1.2	0.04
CA19.9 basal (≥59 ULN versus <59 ULN)	1	0.5–2.2	0.8
CA19.9 reduction (<50% versus ≥50%)	1.8	0.89–3.62	0.098
Stent (yes versus no)	0.58	0.29–1.16	0.12
N/L ratio (≥5 versus <5)	2.47	1.3–4.7	0.005	2.70	1.4–5.2	0.003
Liver metastasis	0.4	0.2–0.8	0.01	0.4	0.18–0.82	0.01